Lv5
1040 积分 2021-06-13 加入
A Bayesian Survival Model to Support the Selection of the Best Hematopoietic Stem Cell Donor
9小时前
已完结
Rituximab Toxicity after Preemptive or Therapeutic Administration for Post-Transplant Lymphoproliferative Disorder
1天前
待确认
Post-transplant lymphoproliferative disorder: Update on treatment and novel therapies
1天前
待确认
Long-Term Clinical Outcomes and B Cell Immune Reconstitution Following Allo-HCT With Prophylactic, Post-Transplant Rituximab
1天前
已完结
Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients
2天前
已完结
Risk factors for EBV reactivation and impact of graft composition following GVHD prophylaxis with rabbit ATG or PTCy
2天前
已完结
Long-Term Efficacy of Epstein-Barr Virus-Specific T Cells for Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disorder after Allogeneic Stem Cell Transplantation: A Real-World Study
2天前
已完结
Efficacy of Low-Dose Rituximab as Preemptive Treatment of EBV DNA-emia After Allogeneic Hematopoietic Stem Cell Transplantation
2天前
已完结
Early prophylactic rituximab reduces EBV infection and PTLD in high-risk patients receiving allogeneic hematopoietic stem cell transplantation
2天前
已完结
Healthcare Resource Utilization and Associated Costs in Patients With Chronic Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation in England
3天前
已完结
皖公网安备34019202002308
